Hologic Inc
NASDAQ:HOLX
Hologic Inc
NASDAQ:HOLX
Price:
75.14 USD
-0.81%
Updated:
May 10, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
15
Current
9
Median
12.6
Industry
Higher
than median
Higher
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=15
Enterprise Value
/
18B
EBITDA
1.2B
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| US |
|
Hologic Inc
NASDAQ:HOLX
|
17.6B USD | 15 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
182.3B USD | 19.1 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
136.9B USD | 56.5 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.9B USD | 24.3 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
109.8B USD | 13.9 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
108.3B USD | 30.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
67.7B USD | 18.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
58.5B EUR | 18.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
52.2B USD | 26.8 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
368.5B CNY | 27.8 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
50.4B USD | 59 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
13.4
2-Years Forward
EV/EBITDA
12.4
3-Years Forward
EV/EBITDA
11.6
You don't have any saved screeners yet
